drugset / Trial / NCT00091910

Research Into the Treatment of Anemia for Critically Ill Patients Admitted to Intensive Care Units (ICU)

NCT00091910

RandomizedSingle-groupDouble-blindDiagnostic

Summary

Erythropoietin (EPO) is a hormone produced in the kidney. Its function is to stimulate the production of red cells in the bone marrow. The purpose of this research study is to demonstrate that the administration EPO to critically ill subjects in the intensive care unit (ICU) reduces the number of patients requiring red blood cell (RBC) transfusion as compared with placebo (a liquid without active medicine).

Timeline

Start
2003-09
Primary completion
Completion
2006-06

Drugs

EvaluationDrugModalityDoseRoute
Subject epoetin alfa Protein / enzyme biologic 40000 iu Subcutaneous

Indications